TABLE 2.
gG-2-based EIA(s) | gG-2-based commercial immunoblot
|
No. of sera positive by IhW/no. retested | ||||
---|---|---|---|---|---|---|
Yielding positive result | Yielding equivocal result | Yielding negative result | No. of sera | Resulta | No. of sera | |
Eu2, Gu2, Ra2 | 52 | Pos | 51 | 14/14b | ||
Neg | 1 | 1/1 | ||||
Eu2, Gu2 | Ra2 | 6 | Pos | 6 | 6/6 | |
Eu2, Gu2 | Ra2 | 30 | Pos | 27 | 26/27 | |
Neg | 3 | 1/3 | ||||
Eu2 | Gu2 | Ra2 | 1 | Pos | 1 | 1/1 |
Eu2 | Gu2, Ra2 | 13 | Pos | 5 | 5/5 | |
Neg | 8 | 2/8 | ||||
Gu2 | Ra2, Eu2 | 1 | Neg | 1 | 0/1 | |
Ra2 | Gu2 | Eu2 | 1 | Neg | 1 | 1/1 |
Ra2 | Eu2, Gu2 | 4 | Neg | 4 | 0/4 | |
Eu2 | Gu2, Ra2 | 1 | Neg | 1 | 1/1 | |
Ra2 | Eu2, Gu2 | 1 | Neg | 1 | 0/1 | |
Eu2, Gu2, Ra2 | 84 | Neg | 84 | 1/81c |
Pos, positive; neg, negative.
Sera were tested when the in-house confirmatory assay was evaluated.
Only HSV-positive sera (n = 81) were retested with the in-house confirmatory assay.